Literature DB >> 9283113

[123I]beta-CIT single-photon emission tomography in Parkinson's disease reveals a smaller decline in dopamine transporters with age than in controls.

G Tissingh1, P Bergmans, J Booij, A Winogrodzka, J C Stoof, E C Wolters, E A Van Royen.   

Abstract

In vivo studies using single-photon emission tomography (SPET) and positron emission tomography have shown an age-related decline in the number of striatal dopamine transporters in healthy subjects. We examined ten healthy subjects and 33 de novo patients with Parkinson's disease (PD) using [123I]2beta-carbomethoxy-3beta-(4-iodophenyl)tropane ([123I]beta-CIT) SPET. A clear age-related loss of dopamine transporters was found in the healthy subjects. In the PD group, controlling for the contribution of disease severity, we found a small (compared with controls) but significant decrease with aging, though only in the ipsilateral regions. This aging effect was especially pronounced in younger patients. We conclude that the use of age-correct SPET data in PD, based on studies with healthy subjects, may lead to an under- or an overestimation of the striatal binding measures.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9283113     DOI: 10.1007/bf01254252

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  9 in total

1.  [(123)I]beta-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson's disease.

Authors:  A Winogrodzka; P Bergmans; J Booij; E A van Royen; J C Stoof; E C Wolters
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-03       Impact factor: 10.154

2.  Early-stage [123I]beta-CIT SPECT and long-term clinical follow-up in patients with an initial diagnosis of Parkinson's disease.

Authors:  Diederick Stoffers; Jan Booij; Lisette Bosscher; Ania Winogrodzka; Erik C Wolters; Henk W Berendse
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-01-29       Impact factor: 9.236

Review 3.  Neuroimaging and therapeutics in movement disorders.

Authors:  Thomas Eckert; David Eidelberg
Journal:  NeuroRx       Date:  2005-04

4.  Comparison of FP-CIT SPECT with F-DOPA PET in patients with de novo and advanced Parkinson's disease.

Authors:  S A Eshuis; R P Maguire; K L Leenders; S Jonkman; P L Jager
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-10-15       Impact factor: 9.236

5.  How useful is [123I]beta-CIT SPECT in clinical practice?

Authors:  J Eerola; P J Tienari; S Kaakkola; P Nikkinen; J Launes
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-09       Impact factor: 10.154

6.  Establishing On-Site Reference Values for (123)I-FP-CIT SPECT (DaTSCAN®) Using a Cohort of Individuals with Non-Degenerative Conditions.

Authors:  Nicolas Nicastro; Valentina Garibotto; Antoine Poncet; Simon Badoud; Pierre R Burkhard
Journal:  Mol Imaging Biol       Date:  2016-04       Impact factor: 3.488

7.  Evaluation of Iterative Reconstruction Method and Attenuation Correction in Brain Dopamine Transporter SPECT Using an Anthropomorphic Striatal Phantom.

Authors:  Akira Maebatake; Ayaka Imamura; Yui Kodera; Yasuo Yamashita; Kazuhiko Himuro; Shingo Baba; Kenta Miwa; Masayuki Sasaki
Journal:  Asia Ocean J Nucl Med Biol       Date:  2016

Review 8.  Dopamine Transporter Imaging, Current Status of a Potential Biomarker: A Comprehensive Review.

Authors:  Giovanni Palermo; Sara Giannoni; Gabriele Bellini; Gabriele Siciliano; Roberto Ceravolo
Journal:  Int J Mol Sci       Date:  2021-10-18       Impact factor: 5.923

Review 9.  Molecular diagnostics of neurodegenerative disorders.

Authors:  Megha Agrawal; Abhijit Biswas
Journal:  Front Mol Biosci       Date:  2015-09-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.